ReviewEuropean respiratory review : an official journal of the European Respiratory Society2026
When clearance fails: the role of efferocytosis in COPD.
Review in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Defective alveolar regeneration in emphysema: identifying dysfunctional cellular crosstalk and novel therapeutic opportunities for tissue repair.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Effects of Inhaled Corticosteroids and Long-Acting β2-Agonists on Efferocytosis and Inflammatory Cell Survival: An In Vitro Study Relevant to COPD and Lung Cancer.International journal of molecular sciences · 2026Article
- Microplastics inhibit macrophage bioenergetics impairing homeostatic function and immune responsiveness.bioRxiv : the preprint server for biology · 2026Article
- The ErbB-tyrosine kinase inhibitor, neratinib, has anti-inflammatory effects in multimorbidity by increasing macrophage efferocytosis via the upregulation of MerTK.Journal of inflammation (London, England) · 2026Article
- The role of programmed cell death in chronic obstructive pulmonary disease: from pathogenesis to treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the enormous global burden associated with chronic obstructive pulmonary disease (COPD), its precise underlying mechanisms remain incompletely understood. A key feature of COPD is persistent, nonresolving inflammation, traditionally attributed to an exaggerated immune response, oxidative stress, protease-antiprotease imbalances and increased cell death. While excessive cell death in COPD is well described, emerging evidence highlights defects in the subsequent clearance process, known as efferocytosis. Effective removal of dead cells is essential to prevent further inflammation in order to maintain tissue homeostasis. In this article, we critically review the literature and highlight the significant impairment of efferocytosis in COPD, as alveolar macrophages from COPD patients show a reduced capacity to engulf apoptotic airway epithelial cells. This impairment appears to be irreversible once COPD has developed, even after smoking cessation. This raises the possibility that impaired efferocytosis may represent an additional pathogenetic mechanism in COPD. We further discuss recent literature on how dysregulation in each of the consecutive steps of efferocytosis, namely the "find-me", "eat-me", uptake and degradation phases, can contribute to COPD pathogenesis. Finally, we propose future directions for both basic and clinical research in COPD and highlight novel therapeutic opportunities aimed at targeting the underlying disease mechanisms, rather than merely addressing symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.